3 Biotech Stocks With a Cash Pile Higher Than Their Valuations
Our roundtable found three biotechs with a nice cash cushion.
Invitae(NVTA)
New York Stock Exchange
NVTA
$4.02
$0.52
14.9%
Price as of May 27, 2022, 4:00 p.m. ET
View Interactive NVTA Charts
Invitae offers medical genetics testing for a variety of diseases, disorders, and pediatric conditions.
Interactive Chart
Compare NVTA Stock to Peers
| Symbol | Last Price | Market Cap | % Δ 1 Yr | % Δ 5 Yr |
|---|---|---|---|---|
|
NVTA
Invitae
|
$4.02 | $922M | -86.2% | -53.0% |
|
EDIT |
$11.68 | $801M | -66.2% | -15.1% |
|
BLUE |
$3.28 | $234M | -84.0% | -93.5% |
|
CMPS |
$8.41 | $358M | -75.9% | |
|
OGI |
$1.46 | $458M | -58.3% | -41.6% |
News & Analysis: Invitae
The Fool has written over 100 articles on Invitae.
Why Invitae Stock Is Tumbling Today
The medical genetics company reported disappointing Q1 results.
Invitae (NVTA) Q1 2022 Earnings Call Transcript
NVTA earnings call for the period ending March 31, 2022.
2 Charts That Explain Invitae's Shortcomings
Invitae is a leading genetic testing company that's been public since 2015. Why has the stock done so poorly?
Why Invitae Stock Rose 10.7% on Tuesday
The molecular diagnostics company is bouncing back from its two-year low.
Invitae (NVTA) Q4 2021 Earnings Call Transcript
NVTA earnings call for the period ending December 31, 2021.
Should You Invest in Invitae Right Now?
Before buying shares, investors need to think about Invitae's most significant red flag.
What Especially Stood Out From Invitae's Q3 Results
The big news from Invitae's Q3 update was a worsening bottom line.
3 Stocks That Could Soar 46% or More, According to Wall Street
Analyst price targets for three top growth stocks suggest big gains just up ahead.
Invitae (NVTA) Q3 2021 Earnings Call Transcript
NVTA earnings call for the period ending September 30, 2021.
